The Lancet Oncology Commission on accelerating equitable access to cancer genomics and precision oncology provides an important framework defining indicators that health systems can and should measure ...
A panel of outside advisers will vote this week on whether to recommend that the Food and Drug Administration grant the first ...
About 1 in 8 men will learn that they have prostate cancer at some point in their lifetime. And while most who are diagnosed will survive, prostate cancer can be serious. It’s the second-leading cause ...
Experts debate the evidence, uncertainties, and readiness for widespread use of GRAIL’s Galleri multicancer early detection ...
Agendia’s landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care ...
A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and ...
A blood test designed to spot signs of multiple cancers in apparently healthy people faces its first major regulatory hurdle ...
Agendia's landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care Agendia, Inc., a leader in precision oncology for ...
The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts will ...
UCLA researchers have created a blood test that can scan DNA signals for multiple cancers, liver diseases, and signs of organ damage—and even indicate where trouble may be developing. Early results ...
Galleri is a multicancer detection test developed by Grail (GRAL), a publicly traded spinoff from sequencing giant Illumina (ILMN). It's marketed directly to Americans who are at least 50 years old on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results